Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 150 of 517 entries
View as:

Study to Investigate Relative Bioavailability of Different Formulations of SHR6390 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04667156 Org: User:
Start: 12/13/20 End: 01/29/21 Due: 01/29/22

A Study to Evaluate the Effect of Itraconazole on Pharmacokinetics (PK) of SHR8554 in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05928988 Org: User:
Start: 01/04/22 End: 06/09/22 Due: 06/09/23

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Oral HRS5091 in Healthy Subjects and Chronic Hepatitis B Patients

Phase: N/A Priority: Normal
NCT ID: NCT04480294 Org: User:
Start: 07/28/20 End: 11/23/21 Due: 11/23/22

A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy

Phase: N/A Priority: Normal
NCT ID: NCT05009290 Org: User:
Start: 11/01/21 End: 10/30/31 Due: 10/30/32

SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04948788 Org: User:
Start: 10/31/21 End: 10/31/23 Due: 10/31/24

SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04282070 Org: User:
Start: 03/27/20 End: 12/15/22 Due: 12/15/23

A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC

Phase: N/A Priority: Normal
NCT ID: NCT04603833 Org: User:
Start: 12/02/20 End: 12/31/22 Due: 12/31/23

Multiple Doses Escalation Study of SHR0302 in Rheumatoid Arthritis (RA) Patients

Phase: N/A Priority: Normal
NCT ID: NCT02665910 Org: User:
Start: 05/31/16 End: - Due: -

A Trial of HR19042 Capsule in Healthy Chinese Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04887532 Org: User:
Start: 07/01/21 End: 07/27/21 Due: 07/27/22

A Phase I Study of Famitinib Malate in Patients With Solid Tumor

Phase: N/A Priority: Normal
NCT ID: NCT01762280 Org: User:
Start: 06/30/09 End: 07/31/12 Due: 07/31/13

A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia （SAA） Patient

Phase: N/A Priority: Normal
NCT ID: NCT03557099 Org: User:
Start: 06/20/18 End: 07/23/20 Due: 07/23/21

Extension Study of Hetrombopag in Severe Aplastic Anemia

Phase: N/A Priority: Normal
NCT ID: NCT04961710 Org: User:
Start: 09/19/19 End: 12/31/24 Due: 12/31/25

A Study to Evaluate the Safety and Efficacy of DDO-3055 in Healthy Volunteers and Patients With Chronic Kidney Disease

Phase: N/A Priority: Normal
NCT ID: NCT03976115 Org: User:
Start: 07/18/19 End: 05/11/21 Due: 05/11/22

Effect of Low-fat Diet on the Pharmacokinetics of Pyrotinib in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04315493 Org: User:
Start: 03/31/20 End: 04/30/20 Due: 04/30/21

A Drug-drug Interaction Trial of Rifampicin Pharmacokinetics Effect on Fluzoparib

Phase: N/A Priority: Normal
NCT ID: NCT04011124 Org: User:
Start: 07/24/19 End: 09/16/19 Due: 09/16/20

Drug-durg Interaction of SHR3680 With Digoxin, Rosuvastatin Calcium and Metformin Hydrochloride

Phase: N/A Priority: Normal
NCT ID: NCT04621669 Org: User:
Start: 11/19/20 End: 07/05/21 Due: 07/05/22

SHR9549 in ER Positive HER2 Negative Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03596658 Org: User:
Start: 07/25/18 End: 10/14/19 Due: 10/14/20

SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.

Phase: N/A Priority: Normal
NCT ID: NCT03558191 Org: User:
Start: 08/14/18 End: 12/30/21 Due: 12/30/22

A Phase 1 Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3167 Single Injection in Healthy Subjects and Patients With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT05996380 Org: User:
Start: 06/09/23 End: 04/28/24 Due: 04/28/25

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT04203485 Org: User:
Start: 06/15/20 End: 05/31/22 Due: 05/31/23

Safety, Tolerability and PK/PD of SHR1459 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT03668509 Org: User:
Start: 09/01/18 End: 03/01/19 Due: 03/01/20

A Clinical Study of Remimazolam Tosilate Compared to Propofol for General Anesthesia During Elective Surgery

Phase: N/A Priority: Normal
NCT ID: NCT03921775 Org: User:
Start: 05/13/19 End: 12/30/19 Due: 12/30/20

A Phase Ⅰa Study of Remimazolam Tosylate in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01970072 Org: User:
Start: 10/14/13 End: 06/20/14 Due: 06/20/15

A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation

Phase: N/A Priority: Normal
NCT ID: NCT02834936 Org: User:
Start: 09/27/16 End: 06/30/18 Due: 06/30/19

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment.

Phase: N/A Priority: Normal
NCT ID: NCT03605706 Org: User:
Start: 05/31/19 End: 12/31/23 Due: 12/31/24